• Eva Montané and Javier Santesmases.
• Servicio de Farmacología Clínica, Hospital Universitari Germans Trias i Pujol, Barcelona, España; Departamento de Farmacología, Terapéutica y Toxicología, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: emontane.germanstrias@gencat.cat.
• Med Clin (Barc). 2020 Mar 13; 154 (5): 178-184.

AbstractAn adverse drug reaction (ADR) is defined as a response to a medicinal product which is noxious and unintended. ADRs are an important cause of morbidity and mortality and increase health costs. The pharmacovigilance systems allow the identification and prevention of the risks associated with use of a drug, especially of recently marketed drugs; they detect signals from data of the global ADR register and also support decisions taken by regulatory agencies in different countries. Only a few drugs are withdrawn from the market, mainly due to hepatotoxicity. Spontaneous notification of ADR is the cheapest, simplest and most used method to recognize new safety drug problems, under-reporting being its main limitation. The future of pharmacovigilance and ADRs will include a higher involvement of patients, doctors, health authorities and pharmaceutical companies, and the use of new technologies.Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

10 keywords...

hide…